Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temozolomide, Carboplatin and Neupogen in High-Grade Gliomas
NCT00006263Phase 2Withdrawn
- Sponsor
- NYU Langone Health
- Start
- Nov 1997
- Modality
- DNA Intercalators/Alkylators, Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of temozolomide, carboplatin, filgrastim in glioma, sponsored by NYU Langone Health. Planned start Nov 1997; status: withdrawn.
02
Drugs
temozolomidecarboplatinfilgrastim
03
Conditions
glioma
Beyond the preview
Go deeper on NCT00006263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00006263.